Prophylaxis for disseminated Mycobacterium avium complex (MAC) infection in patients with AIDS: A cost-effectiveness analysis

Journal of Acquired Immune Deficiency Syndromes and Human Retrovirology

Volumn 15, Issue 4, 1997, Pages 275-282

  Freedberg, Kenneth A ^a,b,c   Cohen, Calvin J ^d,e   Barber, Thomas W ^a  

^a Clinical Economics Research Unit   (United States)

^b BOSTON MEDICAL CENTER   (United States)

^c BOSTON UNIVERSITY SCHOOL OF PUBLIC HEALTH   (United States)

^d Comm Res Initiative of New England ^*  (United States)

^e HARVARD PILGRIM HEALTH CARE   (United States)

Author keywords

Azithromycin; Clarithromycin; Cost effectiveness; Mycobacterium avium complex; Prophylaxis; Rifabutin

Indexed keywords

AZITHROMYCIN; CLARITHROMYCIN; ETHAMBUTOL; RIFABUTIN; RIFAMPICIN;

ANTIBACTERIAL ACTIVITY; ANTIBIOTIC PROPHYLAXIS; ARTICLE; COST EFFECTIVENESS ANALYSIS; DRUG COST; DRUG EFFICACY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; MAJOR CLINICAL STUDY; MALE; MYCOBACTERIOSIS; MYCOBACTERIUM INTRACELLULARE AVIUM; PRIORITY JOURNAL; QUALITY ADJUSTED LIFE YEAR;

HUMAN IMMUNODEFICIENCY VIRUS; MYCOBACTERIUM; MYCOBACTERIUM AVIUM; MYCOBACTERIUM AVIUM COMPLEX; MYCOBACTERIUM AVIUM COMPLEX (MAC); MYCOBACTERIUM AVIUM-INTRACELLULARE; MYCOBACTERIUM INTRACELLULARE;

EID: 0030792751     PISSN: 10779450     EISSN: None     Source Type: Journal    
DOI: 10.1097/00042560-199708010-00005     Document Type: Article

References (44)

1. Horsburgh CR. Mycobacterium avium complex infection in the acquired immunodeficiency syndrome. N Engl J Med 1991;324: 1332-8.
2. Nightingale SD, Byrd LT. Southern PM, Jockusch JD, Cal SX, Wynne BA. Incidence of Mycobacterium avium-intracellulare complex bacteremia in human immunodeficiency virus-positive patients. J Infect Dis 1992;165:1082-5.
3. Benson CA, Ellner JJ. Mycobacterium avium complex infection and AIDS: advances in theory and practice. Clin Infect Dis 1993; 17:7-20.
4. Hoy J, Mijch A, Sandland M, Greyson L, Lucas R, Dwyer B. Quadruple-drug therapy for Mycobacterium avium-intracellulare bacteremia in AIDS patients. J Infect Dis 1990;161:801-5.
5. Horsburgh CR, Selik RM. The epidemiology of disseminated nontuberculous mycobacterial infection in the acquired immunodeficiency syndrome (AIDS). Am Rev Respir Dis 1989;139:4-7.
6. Kerlikowske KM, Katz MH, Chan AK, Perez-Stable EJ. Antimycobacterial therapy for disseminated Mycobacterium avium complex infection in patients with acquired immunodeficiency syndrome. Arch Intern Med 1992;152:813-7.
7. Chiu J, Nussbaum J, Bozzette S, et al. Treatment of disseminated Mycobacterium avium complex infection in AIDS with amikacin, ethambutol, rifampin, and ciprofloxacin. Ann Intern Med 1990; 113:358-361.
8. Kemper CA, Meng TC, Nussbaum J, et al. Treatment of Mycobacterium avium complex bacteremia in AIDS with a four-drug oral regimen. Ann Intern Med 1992;116:466-472.
9. Young LS, Wiviott L, Wu M, et al. Azithromycin for treatment of Mycobacterium avium-intracellulare complex infection in patients with AIDS. Lancet 1991;338:1107-9.
10. Dautzenberg B, Truffot C, Legris S, et al. Activity of clarithromycin against Mycobacterium avium infection in patients with the acquired immunodeficiency syndrome: a controlled clinical trial. Am Rev Respir Dis 1991;144:564-9.
11. Kissinger P, Clark R, Morse A, Brandon W. Comparison of multiple drug therapy regimens for HIV-related disseminated Mycobacterium avium disease. J Acquir Immune Defic Syndr Hum Retrovirol 1995;9:133-7.
12. Wallace RJ, Brown BA, Griffith DE, Girard W, Tanaka K. Reduced serum levels of clarithromycin in patients treated with multidrug regimens rifampin or rifabutin for Mycobacterium avium intracellulare infection. J Infect Dis 1995;171:747-50.
13. Olliaro P, Dautzenberg B. Control of the body burden of Mycobacterium avium complex is associated with improved quality of life and prolonged survival of patients with AIDS: a prospective trial with rifabutin combined with isoniazid, clofazimine, ethambutol. J Chemother 1994;6:189-96.
14. Sullam PM, Gordin FM, Wynne BA. Efficacy of rifabutin in the treatment of disseminated infection due to Mycobacterium avium complex: The Rifabutin Treatment Group. Clin Infect Dis 1994; 19:84-6.
15. Benson CA. Treatment of disseminated disease due to the Mycobacterium avium complex in patients with AIDS. Clin Infect Dis 1994;18(Suppl 3):S237-42.
16. Jorup-Ronstrom C, Julander I, Petrini B. Efficacy of triple drug regimen of amikacin, ethambutol and rifabutin in AIDS patients with symptomatic Mycobacterium avium complex infection. J Infect 1993;26:67-70.
17. Masur H, the Public Health Service Task Force on Prophylaxis and Therapy for Mycobacterium avium complex. Recommendations on prophylaxis and therapy for disseminated Mycobacterium avium complex disease in patients infected with the human immunodeficiency virus. N Engl J Med 1993;329:898-904.
18. Gordin F, Masur H. Prophylaxis of Mycobacterium avium complex bacteremia in patients with AIDS. Clin Infect Dis 1994;18(Suppl 3):S223-6.
19. Nightingale S, Cameron DW, Gordin FM, et al. Two controlled trials of rifabutin prophylaxis against Mycobacterium avium complex infection in AIDS. N Engl J Med 1993;329:828-33.
20. USPHS/IDSA Prevention of Opportunistic Infections Working Group. USPHS/IDSA guidelines for the prevention of opportunistic infections in persons infected with human immunodeficiency virus: disease-specific recommendations. Clin Infect Dis 1995;21(Suppl 1):S32-43.
21. Havlir DV, Dube MP, Sattler FR, et al. Prophylaxis against disseminated Mycobacterium avium complex with weekly azithromycin, daily rifabutin, or both. N Engl J Med 1996;335:392-8.
22. Pierce M, Crampton S, Henry D, et al. A randomized trial of clarithromycin as prophylaxis against disseminated Mycobacterium avium complex infection in patients with advanced acquired immunodeficiency syndrome. N Engl J Med 1996;335:384-91.
23. Wasserman Y. Physicians' fee reference 1994. West Allis. WI: Medical Publishers, 1994.
24. 1994 Redbook. Montvale, NJ: Medical Economics Data, 1994.
25. Weinstein MC, Fineberg HV. Clinical decision analysis Philadelphia: WB Saunders, 1980.
26. Eisenberg J. Clinical economics: a guide to the economic analysis of clinical practice. JAMA 1989;262:2879-86.
27. Torrance GW, Sackett DL, Thomas WH. Utility maximization model for program evaluation: a demonstration application. In Berg, RL, ed. Health status indexes. Chicago, IL: Hospital Research and Education Trust, 1973:156-71.
28. Laupacis A, Feeny D, Detsky AS, Tugwell PX. How attractive does a new technology have to be to warrant adoption and utilization? Tentative guidelines for using clinical and economic evaluations. Can Med Assoc J 1992;146:473-81.
29. Moore RD, Chaisson RE. Survival analysis of two controlled trials of rifabutin prophylaxis against Mycobacterium avium complex in AIDS. AIDS 1995;9:1337-42.
30. Safrin SD, Deschenes J, Miller M, Phillips P, Toma E. Uveitis and pseudojaundice during a regimen of clarithromycin, rifabutin and ethambutol [letter]. N Engl J Med 1994;330:438-9.
31. Frank MO, Graham MB, Wispelwey B. Rifabutin and uveitis [letter]. N Engl J Med 1994;330:868.
32. Fuller JD, Stanfield LED, Craven DE. Rifabutin prophylaxis and uveitis [letter]. N Engl J Med 1994;330:1315-6.
33. Jacobs DS, Piliero PJ, Kuperwaser MG, et al. Acute uveitis associated with rifabutin use in patients with human immunodeficiency virus infection. Am J Ophthalmol 1994;118:716-22.
34. Saran BR, Maguire AM, Nichols C, et al. Hypopyon uveitis in patients with acquired immunodeficiency syndrome treated for systemic Mycobacterium avium complex infection with rifabutin. Arch Ophthalmol 1994;112:1159-65.
35. The DATRI 001 Study Group. Clarithromycin plus rifabutin for MAC prophylaxis: evidence for a drug interaction [abstract]. The First National Conference on Human Retroviruses and Related Infections. Washington, DC, October 13, 1993.
36. Narano PK, Trapnell CB, Schoenfelder JR, Lavelle JP, Blanchine JR. Fluconazole and enhanced effect on rifabutin prophylaxis [letter]. N Engl J Med 1994;330:1316.
37. 3: a cost-effectiveness analysis. J Acquir Immune Defic Syndr 1991;4:521-31.
38. Hillner BE, Smith TJ. Efficacy and cost-effectiveness of adjuvant chemotherapy in women with node-negative breast cancer. N Engl J Med 1991;324:160-8.
39. Krumholz HM, Pasternak RC, Weinstein MC, et al. Cost-effectiveness of thrombolytic therapy with streptokinase in elderly patients with suspected myocardial infection. N Engl J Med 1992; 327:7-13.
40. Edelson JT, Weinstein MC, Tosteson ANA, Williams L. Lee TH, Goldman L. Long-term cost-effectiveness of various initial monotherapies for mild to moderate hypertension. JAMA 1990;263:407-13.
41. Eddy DM. Screening for breast cancer. Ann Intern Med 1989;111: 389-99.
42. Kinosian BP, Eisenberg JM. Cutting into cholesterol: cost-effective alternatives for treating hypercholesterolemia. JAMA 1988;259:2249-54.
43. U.S. Bureau of the Census. Statistical abstract of the United States: 1995. 115th ed. Washington, DC: U.S. Bureau of the Census, 1993.
44. Kravcik S, Toye BW, Fyke K, et al. Impact of Mycobacterium avium complex prophylaxis on the incidence of mycobacterial infections and transfusion-requiring anemia in an HIV-positive population. J Acquir Immune Defic Syndr 1996;13:27-32.